Regeneron Pharmaceuticals, Inc [REGN] stock prices are up 3.06% to $614.79 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The REGN shares have gain 7.08% over the last week, with a monthly amount glided 9.49%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] stock has seen the most recent analyst activity on May 14, 2025, when Citigroup upgraded its rating to a Buy but kept the price target unchanged to $700 for it. On February 05, 2025, upgrade upgraded it’s rating to Outperform and revised its price target to $834 on the stock. UBS downgraded its rating to a Neutral and decreased its price target to $738 on January 16, 2025. Wolfe Research started tracking with a Outperform rating for this stock on November 15, 2024, and assigned it a price target of $1150. In a note dated November 14, 2024, Citigroup initiated an Neutral rating and provided a target price of $895 on this stock.
The stock price of Regeneron Pharmaceuticals, Inc [REGN] has been fluctuating between $520.50 and $1211.20 over the past year. Currently, Wall Street analysts expect the stock to reach $816 within the next 12 months. Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] shares were valued at $614.79 at the most recent close of the market. An investor can expect a potential return of 32.73% based on the average REGN price forecast.
Analyzing the REGN fundamentals
The Regeneron Pharmaceuticals, Inc [NASDAQ:REGN] reported sales of 14.09B for trailing twelve months, representing a drop of -3.70%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at 0.35%, and Net Profit Margin reading is 0.32%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.15 and Total Capital is 0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Regeneron Pharmaceuticals, Inc [NASDAQ:REGN]’s Current Ratio is 4.93. As well, the Quick Ratio is 4.03, while the Cash Ratio is 0.87. Considering the valuation of this stock, the price to sales ratio is 4.71, the price to book ratio is 2.26 and price to earnings (TTM) ratio is 15.65.
Transactions by insiders
Recent insider trading involved McCourt Marion, EVP Commercial, that happened on Nov 01 ’24 when 1000.0 shares were sold. Officer, MARION E MCCOURT completed a deal on Nov 01 ’24 to buy 1000.0 shares. Meanwhile, Director RYAN ARTHUR F sold 100.0 shares on Oct 01 ’24.
